BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mock J, Pellegrino C, Neri D. A universal reporter cell line for bioactivity evaluation of engineered cytokine products. Sci Rep 2020;10:3234. [PMID: 32094407 DOI: 10.1038/s41598-020-60182-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered 4-1BBL fusion protein with "activity on demand". Proc Natl Acad Sci U S A 2020;117:31780-8. [PMID: 33239441 DOI: 10.1073/pnas.2013615117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Corbellari R, Stringhini M, Mock J, Ongaro T, Villa A, Neri D, De Luca R. A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis. Mol Cancer Ther 2021;20:859-71. [PMID: 33632875 DOI: 10.1158/1535-7163.MCT-20-0853] [Reference Citation Analysis]
3 Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, Dakhel Plaza S, Nadal L, Gloger A, Schmidt E, Biancofiore I, Donckele EJ, Samain F, Neri D, Cazzamalli S. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A 2021;118:e2101852118. [PMID: 33850024 DOI: 10.1073/pnas.2101852118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mortensen MR, Mock J, Bertolini M, Stringhini M, Catalano M, Neri D. Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. Oncotarget 2020;11:3972-83. [PMID: 33216834 DOI: 10.18632/oncotarget.27772] [Reference Citation Analysis]